Introduction
Acute myocardial infarction is a major cause of heart failure and death. Rapid reperfusion of the ischaemic myocardium remains the only treatment recommended for attenuating myocardial infarction. However, reperfusion initiates additional lethal injury. This deleterious phenomenon culminates in death of cardiac cells that were viable immediately before myocardial reperfusion. 1 New cardioprotective strategies such as postconditioning (PostC) that directly target the reperfusion phase can improve clinical outcomes of acute myocardial infarction. 2, 3 With the aim to develop a pharmacological strategy able to specifically target reperfusion injury, we investigated putative candidates mimicking PostC treatment using a genome-wide microarray strategy on a myocardial ischaemia-reperfusion mouse model. 4 Among the genes differentially regulated by PostC, we identified an upregulation of the metabotropic glutamate receptor type 1 (mGluR1) compared to ischaemia-reperfusion condition. Interestingly, the role of mGluR1 has been widely described in the brain where it plays a significant protective role in a broad range of diseases in the central nervous system. 5 Indeed, at the cellular level mGluR1 activation can block neuronal injury associated with apoptosis. 6, 7 Protection by mGluR1 occurs mainly at the level of free radical generation induced by oxidative stress and by activation of the Pi 3 kinase/Akt pathway. [8] [9] [10] [11] In addition mGluR1 receptors have been reported to play a key role in neuroprotection during PostC in a rat hippocampal slice model of cerebral ischaemia. 10 While mGluR1 expression was previously described in cardiac tissue, 12, 13 their role is still unknown.
In this context, our study aimed to investigate the role of mGluR1 metabotropic glutamate receptors in cardioprotection against myocardial ischaemia-reperfusion injury in the mouse myocardium
Methods
See details in supplementary material online.
Mice

C57BL/6J (Charles River laboratory) and mGluR1
þ/þ , þ/-and -/-KO mice (B6.129P2-Grm1 tm1Dgen /J strain, the Jackson Laboratory) are handled in the animal facility according to the guidelines set forth by the 'Guide for the Care and Use of Laboratory Animals' published by the US National Institutes of Health (NIH publication 8th Edition, 2011).
Surgical protocol of myocardial ischaemia/reperfusion
Investigation conforms to the Directive 2010/63/EU of the European Parliament. The surgical procedures were approved by the regional Committee for animal research (authorization number CE-LR-0814).
Mice were anaesthetized with an intramuscular (IM) injection of ketamine (50 mg/kg), xylazine (10 mg/kg), and chlorpromazine (1.25 mg/kg). After a second injection of ketamine and xylazine (same doses), a left lateral thoracotomy and a coronary artery ligature were performed.
When reperfusion lasted 60 min, a third administration of ketamine/ xylazine was performed (same doses, IM). For longer reperfusion duration, mice underwent subcutaneous administration of lidocaine (1.5 mg/ kg) and a postoperative awakening in an emergency care unit.
Pharmacological treatments
Drugs were administered intravenously 5 min before reperfusion during the surgical protocol.
ECG recordings and echocardiography
ECG and echocardiographic recordings were performed on sedated mice (1.2% isoflurane) using Emka technologies system and a highresolution echocardiographic system (VevoV R , VisualSonics B.V.).
Infarct size assessment
Infarct size measurements were obtained after dual coloration of left ventricular sections by phtalocyanin blue dye and 2,3,5-triphenyltetrazolium chloride and expressed as a percentage of area at risk.
DNA fragmentation assay
Specific DNA fragmentation was quantified in transmural samples of non-ischaemic or ischaemic areas of left ventricle (LV) using an ELISA kit (Roche Diagnostics) designed to measure the amount of cytosolic oligonucleosome-bound DNA, as previously described. 14 
RNA extraction and quantification by real-time polymerase chain reaction
Total RNAs were extracted from ischaemic regions of LV. RNA samples from IR (n = 9) or PostC (n = 9) hearts were pooled and dedicated to quantitative real-time polymerase chain reaction (PCR) analyses. 4 
Isolation and culture of ventricular cardiomyocytes
Hearts mounted on a Langendorff apparatus were subjected to 1h-ischaemia followed by 1h-reperfusion (IR group). For PostC, 3 periods of 1 min-ischaemia, 1 min-reperfusion were applied after ischaemia (PostC group). At the end of reperfusion, hearts were enzymatically dissociated. Single rod-shape myocytes were plated for calcium imaging and immunohistochemistry experiments.
Measurements of [Ca 2þ ] i
Calcium imaging studies were performed with MetaFluor Imaging System (Molecular Devices) in cells loaded with acetoxymethyl ester of Fura-2 (Molecular Probes Inc.).
Immunostaining
Fixated cells and LV deparaffinized sections were incubated with an antimGluR1 antibody.
Picrosirius red staining
Picrosirius-red staining was performed to evaluate fibrotic extent in heart cross-sections.
Immunoblotting
Western blots were performed from LV protein extracts using anti-AKT and anti-pAKT antibodies. pAKT/AKT ratios were calculated after normalization against a-actinin.
Statistical analysis
Values (mean ± SD) were compared using Kruskal-Wallis test followed by the Dunn's post-test. The analysis of contingency tables was realized using the Fisher's exact test (Fura experiments). Data were analysed with GraphPad Prism 6.0 (GraphPad Software).
Results
Restoration of functional mGluR1s by a PostC stimulus
In a previous study, we identified mGluR1 among the genes that were upregulated upon PostC vs. IR. 4 We first performed QPCR experiments and immunochemistry to compare mGluR1 expression in the LVs of sham-operated (SHAM) mice with those subjected to IR in the absence or presence of a PostC protocol ( Figure 1A) . Our results indicate that mGluR1b expression, which is the main isoform expressed in the mouse myocardium, is 47% decreased at the transcriptional level upon IR vs. SHAM (see Supplementary material on line, Figure S1 ). PostC partially reverses this down-regulation of mGluR1 expression at the transcriptional level ( Figure 1B ) at 1 h of reperfusion. mGluR1 labelling on LV-paraffin sections was detected in cardiomyocytes but also in vessels (co-immunostaining with isolectin B4) and in interstitial tissue ( Figure 1C ). mGluR1 expression in cardiomyocytes was further confirmed in vitro on freshly isolated ventricular cardiac cells from adult mouse heart ( Figure 2 ; see Supplementary material online, Figure S2 ). mGluR1 protein expression was colocalized with dystrophin along the peripheral sarcolemma and also along T-tubules of mouse cardiomyocytes ( Figure 2A ; see Supplementary material online, Figure S3) . 15, 16 In order to study the functional coupling between mGluR1 receptors and intracellular calcium, Fura-2 experiments were designed on isolated cells as in a previous work 13 ( Figure 2B-E) . After an application of glutamate, 48.3% of cardiomyocytes responded by a rise of intracellular calcium when the cells were isolated from hearts subjected to PostC ex vivo prior to enzymatic dissociation vs. 13 .6% for those obtained from IR hearts.
Cardioprotective effect of mGluR1 activation
We investigated whether mGluR1 activation at the time of reperfusion could be cardioprotective in vivo. A bolus of glutamate was injected intravenously 5 min prior to reperfusion in C57Bl6 mice in the presence or 
absence of the mGluR1 selective antagonist YM298198 ( Figure 3A) . A 45%-decrease in infarct size was observed in glutamate-treated mice at 24 h of reperfusion, which was abolished when YM298198 was coinjected with glutamate ( Figure 3B ). In addition, the mGluR1 agonist DHPG administered 5 min before reperfusion was able to mimic the cardioprotective effect of glutamate. This effect was also abolished in the presence of YM298198. Note that there was no statistical difference between AR/LV among groups ( Figure 3C ). As shown on Figure  3D , DNA fragmentation was also decreased in glutamate-treated vs. to IR hearts. This reduction was abolished when glutamate was coinjected with YM298198. Inversely, DHPG was able to reproduce the effect of glutamate on DNA fragmentation, an effect abolished in the presence of YM298198.
Contribution of mGluR1 in PostC cardioprotective effects
mGluR1 is a member of the Gq-coupled receptor family such as adenosine, opioid, or bradykinin receptors whose activation is known to contribute to PostC. 17 To evaluate in vivo the contribution of mGluR1 in PostC-induced cardioprotection, mice were subjected to various protocols in the presence or absence of mGluR1 specific agonist and antagonist ( Figure 4A ). As shown on Figure 4B , the decrease in infarct size due to the application of a PostC stimulus was mimicked by the administration of a bolus of DHPG. No additive effect was observed when the PostC stimulus was associated with DHPG administration. When PostC was applied in the presence of YM298198, the cardioprotective effect was partially abolished. There was no statistical difference between AR/LV among groups ( Figure 4C ). As expected, PostC reduced DNA fragmentation compared to IR conditions and this was significantly reversed by YM298198. Note that DHPG was also able to reduce DNA fragmentation ( Figure 4D ).
Lack of glutamate-induced cardioprotective effect in mGluR1 knockout mice
In order to further support the involvement of mGluR1 in cardioprotection, experiments on mGluR1 -/-knockout mice (KO) were performed.
ECG recordings in those mice did not reveal electrophysiological abnormalities (see Supplementary material online, Table S1 and Figure S4) . Scatter dot blots and means ± SD were plotted for infarct size/AR (in % of area at risk) in IR 24 (n = 6). A 45%-decrease in infarct size was observed in glutamate-treated mice (18.66 ± 3.64, n = 11 for Glu vs. 35.11 ± 6.93 , n = 8 for IR; P = 0.0063), which was abolished when YM298198 was coinjected with glutamate (35.07 ± 5.60, n = 6 for Glu þ YM vs. 18 .66 ± 3.64, n = 11 for Glu; P = 0.0267). DHPG was able to mimic the cardioprotective effect of glutamate (18.66 ± 3.78, n = 7 for DHPG vs. 18 .66 ± 3.64, n = 11 for Glu; P = ns). This effect was abolished in the presence of YM 298198 (39.35 ± 7.35, n = 6 for DHPG þ YM vs. 18 .66 ± 3.78, n = 7 for DHPG; P = 0.0075). (C) There was no statistical difference between AR/LV among groups (P = 0.1625). (D) Scatter dot blots and means ± SD were plotted for internucleosomal DNA fragmentation measured in I vs. NI regions of LV from mice not treated (IR 24 ) or treated by Glu, Glu þ YM, DHPG and DHPG þ YM. DNA fragmentation was decreased in glutamate-treated compared to IR hearts (1.63 ± 0.47, n = 7 for Glu vs. 3.91 ± 0.83, n = 7 for IR 24 ; P = 0.0036). This reduction was abolished when glutamate was co-injected with YM298198 (3.86 ± 1.32, n = 8 for Glu þ YM vs. 1.63 ± 0.47, n = 7 for Glu; P = 0.0076). DHPG was able to reproduce the effect of glutamate (1.73 ± 0.54, n = 9 for DHPG vs. 1.63 ± 0.47, n = 7 for Glu; P = ns), an effect abolished in the presence of YM 298198 (3.50 ± 0.99, n = 9 for DHPG þ YM vs. 1.73 ± 0.54, n = 9 for DHPG; P = 0.0233). Statistical analysis was performed using the Kruskal-Wallis test with the Dunn's post hoc test for multiple comparisons. Statistical significance compared to IR 24 is noted ** for P < 0.01. #, ## are noted for P < 0.05, P < 0.001 vs. Glu; ¶ is noted for P < 0.05 vs. DHPG
Higher mortality was observed in mGluR1 -/-mutants subjected to IR.
For this reason, KO mice were then subjected to I 30 R (30 min of ischaemia; Figure 5A ). Indeed, an increased infarct size (þ55.3%) was observed in the myocardium of mGluR1 -/-mutant compared to wild-type
Figure 5B). As shown on Figure 5C , the results obtained for DNA fragmentation measurements revealed an increased amount of oligonucleosomes detected in the LV of mGluR1 Scatter dot blots and means ± SD were plotted for (I/NI ratio) corresponding to the ratio of soluble nucleosome in the ischaemic vs. the non-ischaemic portion of LV tissues. PostC reduced DNA fragmentation compared to IR (1.30 ± 0.44, n = 9 vs. 5.02 ± 1.67, n = 8, respectively; P < 0.0001). DHPG was able to reduce DNA fragmentation (1.89 ± 0.41, n = 6 for DHPG vs.
1.30 ± 0.44, n = 9 for PostC; P = ns). DNA fragmentation was not significantly different from IR when PostC was applied in presence of YM298198 (2.57 ± 0.55, n = 11 for PostC þ YM vs. 5.02 ± 1.67, n = 8 for IR; P = 0.4202). Statistical analysis was performed using the Kruskal-Wallis test with the Dunn's post hoc test for multiple comparisons. Statistical significance compared to IR is noted ns for P > 0.05, * for P < 0.5, ** for P < 0.01, *** for P < 0.001 and **** for P < 0.0001. Statistical significance compared to PostC is noted # for P < 0.5, ## for P < 0.01, ### for P < 0.001. To further confirm that mGluR1 receptors can contribute to cardioprotection, a bolus of glutamate was administered to mGluR1 -/-mice subjected to I 30 R. We did not observe any cardioprotection induced by glutamate. This lack of cardioprotection was also observed after the application of a bolus of DHPG ( Figure 5D ) despite a similar area at risk in the two groups (P = 0.0784, data not shown).
In order to exclude the possibility that the shortened duration of ischaemia used for mGluR1 -/-mice could be responsible for the lack of glutamate induced-cardioprotection, WT mice were subjected to the I 30 R protocol. Figure 5E shows that in these conditions glutamate treatment was still able to decrease (by 42 .08%) infarct size in vivo. Note that upon a PostC protocol, WT mice were also more protected than KO mice (P** = 0.0081).
3.5 mGluR1 cardioprotection occurs via the PI 3 kinase/Akt pathway PI 3 kinase/Akt is part of RISK (Reperfusion Injury Salvage Kinase) pathway playing a crucial role in preventing reperfusion injury in the myocardium. [18] [19] [20] In addition, mGluR1-mediated neuroprotection is reported to involve this pathway. [8] [9] [10] Then, we investigated the contribution of this cascade in mGluR1-mediated cardioprotection. Wortmannin (WOM), a specific antagonist of PI 3 kinase/Akt, was tested in our model to show the involvement of this signalling pathway during cardioprotection upon a PostC stimulus (see Supplementary material online, Figure  S5 ) and co-administered with glutamate before reperfusion ( Figure 6 ). The cardioprotective effect of glutamate was abolished in presence of WOM at 1 h-and 24 h-reperfusion for infarct size ( Figure 6A ) and DNA fragmentation ( Figure 6B) . KO -/-presented larger infarct size compared to mGluR1 þ/þ mice (38.68 ± 5.23, n = 7 vs. 25 .50 ± 5.43, n = 9; P*** = 0.0002). There was no statistical difference between AR/LV among groups (P = 0.3920, data not shown). (C) Scatter dot blots and means ± SD were plotted for internucleosomal DNA fragmentation in mGluR1 þ/þ and -/-LV. DNA fragmentation was increased in mGluR1 -/-vs. wild-type hearts (3.47 ± 0.74, n = 9 vs. 1.79 ± 0.55; n = 8; P*** = 0.0002).
(D) Neither Glutamate nor DHPG were able to protect mGluR1 -/-hearts (31.49 ± 1.48, n = 4 vs. 38 .68 ± 5.23, n = 7; P = 0.3093 and 31.63 ± 3.37, n = 6 vs.
38.68 ± 5.23, n = 7; P = 0.1322) by contrast to PostC (24.66 ± 2.03, n = 4 vs. 38 .68 ± 5.23, n = 7; P*** = 0.0006). (E) Both Glutamate and PostC were able to decrease infarct size in +/+ mouse hearts (14.77 ± 1.95, n = 5 for Glu vs. 25 .50 ± 5.43, n = 9 for I 30 R; P* = 0.0251 and 17.31 ± 3.51, n = 8 for PostC vs. 25 .50 ± 5.43, n = 9 for I 30 R; P** = 0.0012). Note that upon a PostC protocol, mGluR1 +/+ littermate mice were more protected than KO mice (17.31 ± 3.51, n = 8 for +/+ vs. 24 .66 ± 2.03, n = 4 for -/-P = 0.0081). Figure 6C and D).
Long-term cardioprotection
In order to evaluate if a single bolus-injection of glutamate was able to improve post-infarction functional recovery, an echocardiographic study was performed 15 days before surgery (Basal) and 15 days after MI and reperfusion in the presence or absence of a glutamate bolus administration at reperfusion. Ejection fraction, a strong predictor of cardiac outcomes in clinical setting, 21 measured in mice subjected to 40 min of ischaemia followed by 15 days reperfusion ( Figure 7A ) was decreased if compared to Basal condition. Glutamate-treatment allowed improving contractile function after MI ( Figure 7B) . Longitudinal global strain, correlated to infarct size in mice, 22 was decreased after IR compared to Basal and improved in the glutamate-treated group vs. IR ( Figure 7C ). In addition, fibrosis was evaluated 21 days after MI in Basal, Glu, and IR groups. Measurement of fibrosis area was strongly decreased in Glu vs. IR ( Figure 7D and E).
Discussion
This study provides the first demonstration that cardiac mGluR1 receptors can mediate cardioprotection against IR injury in the mouse heart. Activation of mGluR1 by a single bolus of glutamate administered 5 min prior to reperfusion reduced both infarct size and DNA fragmentation chaemia-reperfusion and were allowed to recover after surgery. Echocardiography was recorded 15 days before (Basal) and 15 days after surgery for both IR (untreated) and Glu (treated) groups. Glutamate injection (47 mg/kg) was performed 5 min before reperfusion. 21 days after surgery mice were sacrificed and fibrosis was assessed on LV paraffin-sections. (B) Ejection fraction (%), decreased in the IR group vs. Basal (39.23 ± 9.31, n = 13 for IR vs. 50.46 ± 4.99, n = 13 for Basal; P** = 0.004) was restored upon glutamate-treatment (49.59 ± 9.62, n = 14 for Glu vs. 39.23 ± 9.31, n = 13 for IR, P* = 0.016 and vs. 50.46 ± 4.99, n = 13 for Basal; P = ns). (C) Longitudinal global strain measured by speckle tracking imaging decreased after IR compared to Basal (-9.47 ± 1.72, n = 13 for IR vs. -17.1 ± 3.54 for Basal, n = 14; P**** < 0.0001) was improved in the glutamate-group (-15.05 ± 4.94, n = 14 for Glu vs. -9.47 ± 1.72, n = 13 for IR; P** = 0.0064 and vs. -17.1 ± 3.54 for Basal, n = 14; P = ns). (D) Representative pictures of red Sirius-stained LV sections. (E) Fibrosis area (presented as scatter dot blots and means ± SD) was 73%-decreased in glutamate-treated vs. IR LV samples (3.34 ± 1.7, n = 5 for Glu vs. 12.37 ± 5.2, n = 5 for IR). Statistical analysis was performed using the Kruskal-Wallis test with the Dunn's post hoc test for multiple comparisons.
. 3 kinase/Akt pathway Wortmannin. This strategy improved post-infarction functional recovery as evidenced by an echocardiographic study performed at 15 days and histological evaluation of fibrosis (21 days post-treatment).
Interestingly, restoration of functional mGluR1s by a PostC stimulus after ischaemia-reperfusion injury was evidenced at the transcriptional level. Because of their localization at the surface membrane of ventricular myocytes, they are probably involved in the cardioprotective effect of ischaemic PostC as described for other Gq-coupled receptors. This is consistent with the fact that mGluR1 KO mice exhibit a larger infarct size compared to wild-type and are resistant to glutamate treatment.
By contrast to the heart, the involvement of mGluR1 in the brain during neuronal ischaemic injury has been well described. Metabotropic glutamate G-coupled receptors are widely distributed in the nervous system and play a key role in neuronal pathophysiological situations. 5, 9, 23 While mGluR1 and mGluR5 have been involved in ischaemia-induced neurotoxicity, 24, 25 several studies have documented that activation of mGluR1 in neurons can also protect against epileptic neuronal sclerosis, ischaemic neuronal injury, oxidative stress and NO-induced programmed cell death. 8, 23, 26 mGluR1 receptors are reported to prevent caspase 3 activity in rat brain endothelial cells and neuronal programmed cell death. 7, 26, 27 They can also regulate the mitochondrial membrane potential, which represents a significant determinant for cell injury as described in neurons and endothelial cells. 7 Whereas mGluR1 expression was already described in cardiac tissue, 12, 13 our results show for the first time their involvement in glutamate-induced cardioprotection against IR injury in the mouse myocardium in vivo. As already reported by Moore-Morris et al., 13 we showed using Fura2 experiments that application of glutamate can be associated with an intracellular calcium rise in isolated adult ventricular cardiomyocytes suggesting functional coupling of mGluR1 to phospholipase C via Gq proteins. This effect was correlated with the exclusive presence of the mGluR1b isoform in the mouse ventricular tissue as evidenced by QPCR experiments in the present study and in a previous work. 13 Immunochemistry experiments revealed expression of mGluR1 at the cardiomyocyte membrane, but also in ventricular vessels. Lin and Maiese have shown that mGluR1 activation provides cytoprotection against free radical NO-induced endothelial injury in cultured endothelial cells. 7 We cannot exclude that mGluR1 receptors in other cell types than cardiomyocytes could contribute to cardioprotection by inhibiting cell death. Regarding the mechanisms underlying mGluR1-mediated cardioprotection, our results clearly evidenced an anti-apoptotic effect induced by glutamate or the mGluR1 agonist DHPG measured either at 1 h or 24 h of reperfusion, supporting the results reported in neuroprotection. 6, 7 Up to now, the cardioprotective effects of glutamate have been attributed to its metabolic role in the malate-aspartate shuttle, which might result from both facilitation of cardiac cell function during anaerobic conditions as well as by favouring a rapid return to optimal function upon restoration of aerobic conditions. 24 Glutamate effects have been attributed to its conversion in alpha-cetoglutarate thus maintaining the levels of the Krebs-cycle intermediates within the mitochondria justifying its use as an additive to cardioplegic solutions. 28, 29 In this case, concentrations of glutamate in the range from mM up to 100 mM have been used. It is expected that glutamate infused at reperfusion following prolonged ischaemia in animal models compensates glutamate leakage of prolonged ischaemia. This glutamate supplementation reported in numerous studies results in reduced infarct size and improved hemodynamic recovery suggesting that glutamate, by restoring energy metabolism, plays an important role in cardioprotection against ischaemia-reperfusion injury. [30] [31] [32] [33] Lofgren et al. 34 have described ex vivo that cardioprotection by L-glutamate mimics protection by classical preconditioning in isolated rat hearts and that both preconditioning and postischaemic glutamate administration reduce infarct size to the same extent, without exhibiting any additive effect. Our results did not evaluate the contribution of the metabolic pathway related to glutamate infusion but evidence for the first time in vivo the crucial role of mGluR1 receptors activated at reperfusion by a rather low concentration of glutamate. The data are not mutually exclusive but may suggest a dual and timedependent effect of glutamate in the reperfused ischaemic myocardium: an early phase would rely on mGluR1 activation and a subsequent late phase would control metabolic-dependent hemodynamic effects. In a previous study, Povlsen et al. 32 already suggested a dual effect of glutamate in ex vivo reperfused heart. Our main hypothesis is that the reduction of infarct size by a single bolus of glutamate activating mGluR1 receptors has beneficial functional effects on the myocardium as supported both by our echocardiographic exploration at 15 days post-reperfusion and by our post-mortem fibrosis quantification. Indeed, we evidenced 15 days post-treatment an improvement of both ejection fraction (a strong predictor of cardiac outcomes in clinical setting) and the longitudinal strain (correlated with infarct size in mice and reported as an independent predictor of mortality in high-risk patients with MI). 21, 22, 35 In addition, changes in myocardial longitudinal strain were more marked than changes in conventional LV measures, even shortening fraction (see echocardiographic results in Supplementary material online, supplemen tal data).
36
PI 3 kinase/Akt is part of RISK pathway playing a crucial role in preventing reperfusion injury in the myocardium. [18] [19] [20] Moreover, this pathway has been widely described to be a key component mediated upon both preconditioning and PostC in the heart. This pathway is reported to be activated by other G-coupled receptors known to induce cardioprotection, i.e. adenosine, opioid receptors. 17 Interestingly, ours results are also consistent with previous data in brain reporting the crucial role of the PI 3 kinase/Akt signalling pathway in mGluR1-induced neuroprotection against neuronal injury. [8] [9] [10] In our study, the crucial role of the mGluR1-PI 3 kinase/Akt signalling pathway in cardioprotection, is highlighted by the loss of cardioprotection with PI 3 kinase/Akt inhibitors. Interestingly, DHPG was able to evoke a pharmacological PostC leading to neuroprotection via a PI 3 kinase dependent pathway. 10 In C57Bl6 mice, the beneficial effect of cardiac ischaemic PostC in vivo was significantly reduced in the presence of YM298198, a mGluR1 antagonist. On the other hand, DHPG, a selective agonist administered 5 min before reperfusion in vivo, was able to mimic PostC. Previous experiments focused on metabolic effects of glutamate have also reported the absence of additive effects of ischaemic preconditioning and glutamate administration for reducing infarct size in isolated rat. 34, 37 We also did not observe any additive effect when PostC was applied in presence of the mGluR1 agonist DHPG. Altogether, our data on C57Bl6 mice suggest that mGluR1 might contribute to the cardioprotective effect of PostC. Nevertheless, experiments performed in mGluR1 KO mice seem to minimize this contribution in PostC because PostC was still able to protect the mutant hearts. However, the fact that smaller absolute values of infarct size were observed in +/+ vs. -/-postconditioned hearts suggest that PostC-induced cardioprotection is maximal in presence of mGluR1. This is corroborated by the lack of glutamate-induced cardioprotection in those mutants. The conclusion from these results is that mGluR1s play a key role in glutamate-induced cardioprotection and can be involved in ischaemic PostC as reported for several other GPCR.
Our transcriptomic approach evidenced that the PostC stimulus allowed restoring mGluR1 expression depressed by the IR insult. The increased mGluR1 expression observed at reperfusion in the presence of a PostC protocol can enhance the downstream PI 3 -kinase pathway possibly by a Gq-dependent calcium release. One can speculate that mGluR1 receptors may share this pathway with other Gq-coupled receptors stimulated by autacoids, i.e. adenosine, opioid receptors, already known for mediating cardioprotection. 38 It has also been described that mGluR1 receptors can associate with adenosine receptors in heteromeric complexes and modulate their activity in vitro. 39 In addition, hypobaric hypoxic preconditioning was reported to modulate the group I mGluRs/PLC/IP3Rs/Ca 2þ pathway to induce brain tolerance to anoxia. 40 One can ask the question of the short delay observed for the restoration of mGluR1 measured at 1 h reperfusion. A recent study demonstrates a rapid increase (30 min) in mGluR1 trafficking and membrane expression leading to neuroprotection. 9 A similar hypothesis could be raised to partly account for rapid upregulation of cardiac mGluR1 receptors triggered by PostC. It has been reported that intracellular trafficking of mGluR1 is linked to the small G protein Rab8. This mechanism requires interactions with the extended mGluR1 C-tail, which exists only in the mGluR1a isoform. 41 For mGluR1b neuronal isoforms, other mechanisms have been reported. Indeed, to be released from the endoplasmic reticulum, the mGluR1 retention signal (RRRK motif) needs to be neutralized via protein interactions with mGluR1a or other proteins. 42 A complete biochemical study is required in cardiac tissue to find the protein partners that interact with mGluR1b as reported in the brain and to identify the mechanisms underlying mGluR1b trafficking. 43 In conclusion, our results evidence that a single bolus of glutamate administered prior to reperfusion significantly decreases infarct size in the mouse heart in vivo. They demonstrate that mGluR1 receptors play a critical role in the mechanisms of glutamate-induced cardioprotection via the activation of the RISK pathway. Of interest, the results of clinical trial Glutamics on 861 patients with acute coronary syndrome undergoing coronary artery bypass graft reported that glutamate infusion, even if no reduction in mortality or biomarkers of infarction were observed, decreased the risk of developing severe circulatory failure (secondary outcome). Moreover, Glutamics trial reported the lack of toxicity associated to glutamate treatment. 44 Considering that mGluR1 expression has been evidenced in the human heart, these data altogether may open clinical perspectives.
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